Related Experiment Videos
[New trends in assessment in anticancer treatments by phase II clinical trials]
J R Medioni1, Y D Rycke, B Asselain
1Unité de biostatistique, Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05.
Abstract:
The aim of phase II clinical trials in oncology is to judge if a new treatment have a sufficient antitumor activity to justify further studies. They represent a crucial step in a new anticancer therapy development. The aim is to present phase II clinical trials planification and interpretation methods, end points, recent methods and news in tumor response assessment. Changes of the place of phase II clinical trials in a new treatment development strategies are finally shown. Non randomized trials planification methods (unique analysis, Gehan's method, Simon's procedure, Fleming's multi-stages procedure, triangular test) are described. Usual primary end point is tumor size diminution. Some studies are interested in secondary end points like survival data or treatment toxicity. New planification methods are exposed : randomized phase II clinical trials, phase II within a phase III trial, cross-over studies and bayesian theories are presented. Recent tumor response evaluation theories ("Recist") are described. Phase II trials function in new treatment development is progressing : they could be sufficient, in some cases, to allow a temporary marketing authorization if a treatment show great efficacy. Global reflection upon new treatment and methods allowing marketing authorization is required.
Insights
Phase II clinical trials in oncology assess antitumor activity to guide new cancer therapy development. This includes planning, interpretation, endpoints, and response assessment, influencing treatment strategies and potential marketing authorization.
Area of Science:
- Oncology
- Clinical Trials
- Drug Development
Context:
- Phase II clinical trials are pivotal in oncology for evaluating new anticancer therapies.
- Assessing antitumor activity is crucial to determine if a treatment warrants further investigation.
- These trials bridge early-stage research and late-stage development, impacting treatment strategies.
Purpose:
- To detail the planning and interpretation methodologies for phase II oncology trials.
- To review primary and secondary endpoints, including tumor response and survival data.
- To explore recent advancements in tumor response assessment and trial designs.
Summary:
- The abstract covers non-randomized trial designs (e.g., Simon's procedure) and common endpoints like tumor size reduction.
- It introduces novel approaches such as randomized phase II trials, Bayesian methods, and integrated trial designs.
- Recent evaluation criteria like RECIST and the evolving role of phase II trials in accelerated marketing authorization are discussed.
Impact:
- Provides a comprehensive overview of phase II trial strategies in oncology.
- Highlights the evolving role of these trials in accelerating the development and approval of novel cancer treatments.
- Emphasizes the need for updated strategies and global reflection on drug development pathways.